Using Artificial Intelligence & Machine Learning to Accelerate Rare Disease Drug Development
How AI and machine learning tools are transforming rare disease drug development by accelerating discovery, diagnosis, and patient recruitment.
Rare disease drug development faces significant challenges, such as small patient populations and diverse treatment responses. Leveraging artificial intelligence (AI) and machine learning (ML) can enhance trial efficiency, reduce costs and improve patient access to new therapies.
AI's potential in drug development has surged, enabling the identification of new drug candidates and repurposing existing drugs, the mining unstructured data like electronic health records to identify rare disease patients and expedite diagnosis and overall revolutionizing drug discovery by overcoming traditional challenges with advanced algorithms.
In this white paper, experts explore how AI and ML are transforming rare disease drug development, offering significant potential to accelerate effective treatments and improve patient outcomes.
Fill out the form below to download the white paper.
Related Content
Looking for exclusive insight?
